Cumberland Pharmaceuticals (NASDAQ:CPIX) Downgraded by ValuEngine
Separately, Zacks Investment Research upgraded shares of Cumberland Pharmaceuticals from a hold rating to a buy rating and set a $6.00 price objective on the stock in a research note on Wednesday, August 21st.
Shares of NASDAQ CPIX opened at $5.14 on Tuesday. Cumberland Pharmaceuticals has a fifty-two week low of $4.70 and a fifty-two week high of $7.00. The firm’s 50-day simple moving average is $5.51 and its 200 day simple moving average is $5.87. The company has a quick ratio of 1.85, a current ratio of 2.33 and a debt-to-equity ratio of 0.37. The stock has a market cap of $80.94 million, a P/E ratio of 30.97 and a beta of 0.15.
In other Cumberland Pharmaceuticals news, Director Gordon R. Bernard sold 4,000 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $6.36, for a total value of $25,440.00. Following the sale, the director now directly owns 86,319 shares in the company, valued at $548,988.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gordon R. Bernard sold 13,264 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $6.31, for a total transaction of $83,695.84. Following the completion of the sale, the director now owns 86,319 shares in the company, valued at $544,672.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 4,534 shares of company stock worth $28,179 and have sold 63,739 shares worth $382,548. 39.38% of the stock is owned by insiders.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Cumberland Pharmaceuticals by 17.2% in the second quarter. BlackRock Inc. now owns 332,543 shares of the specialty pharmaceutical company’s stock worth $2,118,000 after acquiring an additional 48,753 shares in the last quarter. Renaissance Technologies LLC raised its position in Cumberland Pharmaceuticals by 13.0% in the second quarter. Renaissance Technologies LLC now owns 441,577 shares of the specialty pharmaceutical company’s stock worth $2,813,000 after acquiring an additional 50,800 shares in the last quarter. Acadian Asset Management LLC raised its position in Cumberland Pharmaceuticals by 6.9% in the second quarter. Acadian Asset Management LLC now owns 104,498 shares of the specialty pharmaceutical company’s stock worth $665,000 after acquiring an additional 6,765 shares in the last quarter. Finally, Bailard Inc. bought a new stake in Cumberland Pharmaceuticals in the second quarter worth about $92,000. Hedge funds and other institutional investors own 31.03% of the company’s stock.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
See Also: Trading Penny Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.